Pfizer invests in neuroscience start-up | January 29, 2018 Issue - Vol. 96 Issue 5 | Chemical & Engineering News
Volume 96 Issue 5 | p. 15 | Concentrates
Issue Date: January 29, 2018

Pfizer invests in neuroscience start-up

By Ryan Cross
Department: Business
Keywords: Neuroscience, MindImmune, Pfizer, neuroinflammation, Alzheimer's, immune

Just two weeks after deciding to ax its neuroscience research efforts, Pfizer has signed a deal with neuroinflammation-focused MindImmune Therapeutics. The biotech firm was founded at the University of Rhode Island in 2016 by former Pfizer employees, including MindImmune CEO Stevin Zorn. The start-up will develop drugs that target peripheral immune system cells, aiming to treat conditions of the central nervous system, including Alzheimer’s disease. The deal signals continued interest in alternatives to the classic amyloid-β and tau protein targets of Alzheimer’s drugs, all of which have failed thus far.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment